ArticlePharmaceutical research2026
Central Composite Design-Optimized Dabigatran Etexilate Cubosomes for Sustained Oral Release and Enhanced In Vivo Pharmacokinetics.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDabigatran etexilate mesylate (DEM), a prodrug of the direct thrombin inhibitor dabigatran used for stroke prevention in nonvalvular atrial fibrillation, exhibits poor aqueous solubility, P-glycoprotein-mediated efflux, and limited oral bioavailability, which pose challenges for oral delivery. This study aimed to develop and optimize a cubosome-based nanocarrier system to enhance the oral bioavailability and sustain the release of DEM.
methodsDEM-loaded cubosomes were prepared using glycerol monooleate (GMO) and Poloxamer 407 by melt dispersion-emulsification. A Central Composite Design (CCD) was employed to optimize formulation variables based on particle size, entrapment efficiency, and drug release responses. Optimized formulations were characterized by dynamic light scattering, TEM, FT-IR, DSC, and XRD analyses. In vitro drug release and in vivo pharmacokinetic studies in Wistar rats were performed to evaluate sustained release behavior and relative oral bioavailability enhancement.
resultsThe optimized cubosomes exhibited nanoscale particle size (~ 19-30 nm), narrow size distribution, high entrapment efficiency (~ 87%), and sustained biphasic drug release up to 24 h. Structural characterization supported incorporation of DEM within the lipid matrix and reduced drug crystallinity. In vivo pharmacokinetic evaluation demonstrated prolonged plasma exposure and enhanced relative bioavailability compared with the marketed formulation, with approximately 2.28-fold higher relative bioavailability.
conclusionsThe optimized cubosomal system effectively improved the oral delivery and sustained release of DEM. The formulation demonstrated enhanced relative bioavailability and prolonged systemic exposure, supporting further development for oral DEM delivery. Anticoagulant efficacy, gastrointestinal safety, and appropriate dosing regimens remain to be established.
Indexed as
Identifiers
42786368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.